Abstract 128P
Background
Rectal cancer (RC) is a significant health concern, ranking as a prevalent form of colorectal cancer, which is third most common cancer diagnosed in both men and women in the United States. The estimations for 2023 project 106,970 new cases of colon cancer and 46,050 new cases of RC, highlighting the urgency to develop potential therapies for RC. Here, a network-based drug repurposing strategy was devised to identify drugs with the potential for repurposing as immune checkpoint inhibitors specifically for RC.
Methods
The study involved constructing a network of RC-associated immune checkpoint proteins (ICPs) and their induced protein interactions (P-ICP). Through network analysis, key target genes closely interacting with ICPs were identified. This was followed by network proximity analysis in the drug-target interaction (DTI) network and pathway cross-examination to identify potential immune checkpoint inhibitors among 109 distinct pathways associated with approved drugs.
Results
The developed approach successfully predicted 19 FDA-approved drugs with potential to target RC-associated ICP-induced pathways. Notably, three of these drugs including Bevacizumab, Cetuximab, and Capecitabine have already been utilized in RC treatment, validating the effectiveness of the strategy. Furthermore, six of the predicted drugs possess immunomodulatory properties, highlighting their potential in immune-related therapeutic applications. The analysis categorized the predicted pathways into two distinct groups: 13 immune pathways and 88 metabolic pathways, indicating the drugs' versatility in targeting different aspects of RC.
Conclusions
The network-based drug repurposing strategy presented in this study offers new opportunities for the rapid repurposing of FDA-approved medications in clinical trials for EC treatment. The identification of 19 drugs with potential immune checkpoint inhibitor properties and insight into useful drug combinations through drug-drug correlation analysis provide valuable contributions to the search for effective therapies against RC. These findings pave the way for further investigations and expedited development of potential treatments for this prevalent cancer type.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Research Foundation (NRF), Korea, under project BK21 FOUR.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract